Ethylene oxide (EO) residual testing is a critical quality control requirement for single-use medical consumables sterilized with ethylene oxide gas, ensuring that toxic residues remain within safe limits before product release. This testing verifies compliance with internationally recognized standards such as ISO 10993-7 and GB/T 16886.7, protecting patients from exposure to residual EO and ethylene chlorohydrin (ECH). This article provides a comprehensive overview of the testing standards, sample types, analytical methods, and regulatory applications involved in EO residue detection for disposable medical devices.
Technical Overview
Ethylene oxide sterilization is the preferred method for single-use medical consumables made from heat- and moisture-sensitive polymeric materials, because it can be performed at low temperatures (typically 37–60 °C) while offering excellent penetration through packaging and complex device geometries. However, ethylene oxide is toxic, irritating to mucous membranes, and classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC). After sterilization, EO gas and its reaction byproduct ethylene chlorohydrin (ECH, 2-chloroethanol) can remain adsorbed on plastics, rubbers, and nonwoven materials, gradually migrating out during clinical use and potentially causing irritation, hemolysis, sensitization, or systemic toxicity in patients.
For this reason, regulatory authorities worldwide, including NMPA, FDA, and EU notified bodies under the EU MDR, require manufacturers of single-use consumables to demonstrate that EO and ECH residuals are below the tolerable limits defined in ISO 10993-7 and its Chinese equivalent GB/T 16886.7. Testing is typically performed using headspace gas chromatography in accordance with GB/T 14233.1 and related pharmacopeial or international methods, forming an essential part of sterilization validation, product registration, and routine batch release.
Testing Samples
Infusion, Transfusion and Injection Consumables
This category includes disposable sterile syringes, injection and infusion needles, intravenous infusion sets, blood transfusion sets, infusion filters, indwelling needles, and blood collection tubes. These products contact blood or parenteral fluids directly, making strict residual control especially important.
Catheters and Tubing Products
Urinary catheters, endotracheal tubes, suction catheters, central venous catheters, drainage tubes, and various flexible polymer tubings are sterilized with EO because of their thermoplastic construction and long lumens that retain gas residues.
Dressings and Surgical Consumables
Gauze and nonwoven dressings, absorbent pads, surgical drapes, gowns, caps, masks, and adhesive bandages are highly adsorbent materials that can retain significant EO residues and therefore require verification after aeration.
Laboratory and Diagnostic Consumables
Pipette tips, Petri dishes, cell culture plates, sample collection and transport tubes, swabs, and cuvettes sterilized with ethylene oxide are tested to ensure residuals do not interfere with laboratory procedures or biosafety.
Extracorporeal Circulation and Dialysis Products
Hemodialyzers, blood tubing sets, oxygenators, plasma filters, and related extracorporeal circuit consumables involve large polymeric surface areas in direct blood contact, requiring rigorous EO and ECH residual evaluation.
Testing Items
The core testing program for single-use consumables includes the following items:
- Ethylene oxide (EO) residual concentration, reported in µg/g or as the total delivered dose per device (mg/device).
- Ethylene chlorohydrin (ECH) residual concentration, evaluated for products where chlorinated materials or saline contact may generate this byproduct.
- Ethylene glycol (EG) residual evaluation, where applicable based on product composition and intended use.
- Assessment of measured residuals against the tolerable exposure limits of ISO 10993-7 / GB/T 16886.7.
According to ISO 10993-7, the tolerable limits depend on the duration of patient contact. For limited exposure devices (contact ≤ 24 hours), the maximum delivered dose is 4 mg for EO and 9 mg for ECH per device. For prolonged exposure devices (24 hours to 30 days), the limits are reduced to 2 mg plus 0.1 mg per day for EO and 2 mg plus 2 mg per day for ECH. For long-term or permanent contact devices (more than 30 days), the limits are 0.1 mg/day for EO and 2 mg/day for ECH. In addition, specific national product standards in China, such as those for infusion and transfusion sets, may impose stricter acceptance criteria, commonly referencing an EO residual limit of 10 µg/g.
Testing Methods
Ethylene Oxide Determination by Headspace Gas Chromatography
The standard approach is headspace gas chromatography with flame ionization detection (HS-GC-FID). A representative portion of the sample is cut into small pieces, accurately weighed (typically 1.0–2.0 g), and placed into a 20 mL headspace vial with a defined volume of purified water. The sealed vial is equilibrated at approximately 60 °C for 30–40 minutes, allowing residual EO to partition into the headspace. An aliquot of the headspace gas is then injected into the gas chromatograph, and EO is identified by retention time and quantified against an external calibration curve prepared from certified EO standard solutions.
Ethylene Chlorohydrin Determination
ECH is highly water-soluble and less volatile than EO. Samples are extracted with water under controlled conditions, and the extract is analyzed by gas chromatography with FID detection using either direct liquid injection or headspace techniques depending on the validated method. Quantification is performed using an external standard calibration, with identification confirmed by retention time.
Extraction Strategies
ISO 10993-7 defines two principal extraction concepts that determine how results are interpreted:
- Simulated-use extraction: designed to mimic the dose actually delivered to the patient during normal clinical use, commonly applied for routine product release testing.
- Exhaustive extraction: extracts at least 90% of the available residue and is mainly used during sterilization process validation to establish the total residual burden.
Typical chromatographic conditions include a capillary column suited for volatile analytes (for example, a 6% cyanopropylphenyl / 94% dimethyl polysiloxane phase), injector temperature near 200 °C, FID detector temperature near 250 °C, and nitrogen or helium as carrier gas. Method performance is confirmed through calibration linearity (typically R² > 0.995), replicate analysis, recovery studies, and detection limits generally in the range of 0.1–0.5 µg/mL. The final result is calculated from the calibrated solution concentration, extraction volume, and sample mass, and expressed as µg/g of device or converted to the total delivered dose per device for comparison against the applicable limit.
Applications
EO residual testing for single-use consumables supports multiple regulatory and quality objectives:
- Regulatory registration and submission, including NMPA type testing, FDA 510(k) premarket notifications, and CE technical documentation under the EU MDR.
- Sterilization process validation (IQ/OQ/PQ) and optimization of aeration or degassing cycles to minimize residual levels.
- Routine batch release testing before products are distributed to market.
- Shelf-life and post-sterilization aging studies to confirm that residuals remain controlled throughout the labeled storage period.
- Change control evaluation following modifications to materials, packaging, load configuration, or sterilization parameters.
- Supplier verification and third-party compliance audits for contract sterilization services.
FAQ
Why must single-use consumables be tested for EO residues?
Because ethylene oxide is a toxic and carcinogenic gas that remains adsorbed in polymer materials after sterilization. Residual EO and ECH can migrate into patients during use, so manufacturers must verify that residuals fall within safe tolerable exposure limits before releasing products.
Which standards govern EO residual testing?
The primary standards are ISO 10993-7 and GB/T 16886.7 for the evaluation of acceptable limits, along with GB/T 14233.1 and related gas chromatographic methods for the analytical determination of EO and ECH in medical consumables.
What are the acceptance criteria for EO residues?
Limits depend on patient contact duration as defined in ISO 10993-7: up to 4 mg EO and 9 mg ECH per device for contact within 24 hours, with progressively lower daily limits for prolonged and long-term contact devices. Product-specific national standards may impose stricter limits such as 10 µg/g.
When should samples be collected after sterilization?
Samples should be collected after the aeration phase is complete and under conditions representative of product shipment and use. Many manufacturers test at defined post-sterilization intervals to demonstrate that residuals at the point of clinical use remain below the applicable limits.
How much sample is required for testing?
A typical test requires a minimum of three to ten sterile units in original packaging, with an additional three units reserved for retesting if necessary. Samples should be shipped at ambient temperature, protected from excessive heat, and received with sterilization batch records for accurate evaluation.
What is the difference between EO and ECH?
EO is the sterilant gas itself, while ECH (2-chloroethanol) is a toxic reaction byproduct formed when EO reacts with chloride-containing materials or solutions. Both residuals are regulated separately under ISO 10993-7 with their own tolerable limits and analytical procedures.
How long does the testing take?
Standard EO and ECH residual testing using headspace gas chromatography is generally completed within five to ten working days after sample receipt, depending on sample quantity, method validation requirements, and reporting needs.